Media
Press releases
15Jul
Regulatory press release
Hansa Biopharma interim report Jan-June 2021
09Jul
Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation
01Jul
Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update
Media assets
Executive Leadership Team
Dr Christian Kjellman
Senior Vice President, Chief Scientific Officer, Research and Development
